España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Gilead Sciences
GILD
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$97.20
0.25
0.26%
At close: -
$96.70
-0.50
-0.51%
After Hours: 4:56 PM EDT
Get Report
Comment
Q4 2024 Earnings in 10 days from now on Tue Feb 11th, after the market close
Gilead Sciences (GILD) Forecast
News
Earnings
Gilead Sciences (GILD) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Gilead Sciences (NASDAQ:GILD) Stock
Gilead Sciences Stock (NASDAQ: GILD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, January 31, 2025
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Nabaparna Bhattacharya
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
Thursday, January 30, 2025
Cognizant And Gilead Expand Partnership To Dr...
Benzinga Newsdesk
Wednesday, January 29, 2025
Looking At Gilead Sciences's Recent Unusual Options Activity
Benzinga Insights
Breaking Down Gilead Sciences: 22 Analysts Share Their Views
Benzinga Insights
JP Morgan Maintains Overweight on Gilead Scie...
Benzinga Newsdesk
Monday, January 27, 2025
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Benzinga Insights
Monday, January 20, 2025
8 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Thursday, January 16, 2025
"Seladelpar Approved To Treat Adult Patients ...
Benzinga Newsdesk
Monday, January 13, 2025
Gilead Exec Says Co Expects To Do "Something ...
Benzinga Newsdesk
Reported Saturday, Gilead And LEO Pharma Join...
Benzinga Newsdesk
Friday, January 10, 2025
This McDonald's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Avi Kapoor
Morgan Stanley Upgrades Gilead Sciences to Ov...
Benzinga Newsdesk
Thursday, January 09, 2025
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Vandana Singh
Wednesday, January 08, 2025
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Vandana Singh
Compugen Announced That The First Patient Was...
Lekha Gupta
Tuesday, January 07, 2025
Looking Into Gilead Sciences's Recent Short Interest
Benzinga Insights
Monday, January 06, 2025
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Benzinga Insights
Tuesday, December 31, 2024
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday
Chris Katje
Sunday, December 22, 2024
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Vandana Singh
Thursday, December 19, 2024
Gilead Sciences Acquires 7.85M Xilio Therapeu...
Benzinga Newsdesk
(GILD) - Analyzing Gilead Sciences's Short Interest
Benzinga Insights
Assembly Biosciences Announces $30.1M Equity ...
Benzinga Newsdesk
Tuesday, December 17, 2024
Gilead Announces FDA Breakthrough Therapy Des...
Benzinga Newsdesk
Gilead Sciences And Terray Therapeutics Have ...
Benzinga Newsdesk
Monday, December 16, 2024
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
Friday, December 13, 2024
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Vandana Singh
Gilead Sciences Says Committee For Medicinal ...
Benzinga Newsdesk
Thursday, December 12, 2024
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Vandana Singh
Wednesday, December 11, 2024
Cantor Fitzgerald Reiterates Neutral on Gilea...
Benzinga Newsdesk
RBC Capital Reiterates Sector Perform on Gile...
Benzinga Newsdesk
Tuesday, December 10, 2024
What Analysts Are Saying About Gilead Sciences Stock
Benzinga Insights
B of A Securities Reinstates Buy on Gilead Sc...
Benzinga Newsdesk
Oppenheimer Maintains Outperform on Gilead Sc...
Benzinga Newsdesk
Monday, December 09, 2024
Gilead Company Kite Reports Results From Five...
Benzinga Newsdesk
Kite, A Gilead Company Presents Longest Follo...
Benzinga Newsdesk
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Vandana Singh
Reported Sunday, Gilead's Kite Highlights New...
Benzinga Newsdesk
Tuesday, December 03, 2024
Looking At Gilead Sciences's Recent Unusual Options Activity
Benzinga Insights
Gilead And Tubulis Enter Exclusive Option And...
Benzinga Newsdesk
Thursday, November 28, 2024
Insider Activity Update: Jeffrey Bluestone Executes Options Exercise, Resulting In $317K At Gilead Sciences
Benzinga Insights
Wednesday, November 27, 2024
Gilead Says NEJM Published Full Results From ...
Benzinga Newsdesk
Monday, November 25, 2024
Price Over Earnings Overview: Gilead Sciences
Benzinga Insights
Thursday, November 21, 2024
UBS Maintains Neutral on Gilead Sciences, Rai...
Benzinga Newsdesk
Mizuho Maintains Outperform on Gilead Science...
Benzinga Newsdesk
Monday, November 18, 2024
26 Analysts Assess Gilead Sciences: What You Need To Know
Benzinga Insights
RBC Capital Maintains Sector Perform on Gilea...
Benzinga Newsdesk
Friday, November 15, 2024
Shares of pharmaceutical and healthcare stock...
Benzinga Newsdesk
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Vandana Singh
Gilead's Livdelzi (Seladelpar) Shows Sustaine...
Benzinga Newsdesk
Show More
